...
首页> 外文期刊>Retina >Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in behcet disease
【24h】

Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in behcet disease

机译:玻璃体腔内甲氨蝶呤和房水细胞因子水平对难治性视网膜血管炎患者行为的影响

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The purpose of this study was to demonstrate the effect of intravitreal methotrexate (MTX) in the treatment of refractory retinal vasculitis due to Behcet disease and to evaluate the changes in aqueous humor cytokines after intravitreal MTX. METHODS: Seven eyes of seven patients with Behcet disease were assessed. Patients had unilaterally active retinal vasculitis that failed to respond to conventional treatment, together with a history of increased intraocular pressure or intolerance to corticosteroid administration. Intravitreal injection of 400 μg MTX was given monthly until visual acuity and intraocular inflammation were stable. Aqueous humor samples were obtained from the patients before MTX injection and from nine eyes during cataract surgery as a control group. Changes in visual acuity with the Early Treatment Diabetic Retinopathy Study Chart, fluorescein angiographic leakage, and ocular complications associated with intravitreal injection were analyzed. Aqueous humor cytokine levels were measured by proteomic analysis using a multianalyte biochip array system. RESULTS: Visual acuity improved significantly during a mean follow-up of 24.9 ± 8.2 weeks with a mean improvement from baseline visual acuity of 3.3 ± 2.6 lines after a mean of 4.3 ± 1.0 injections. Six patients (85.7%) showed an increase in visual acuity by 3 or more lines, and 4 patients exhibited a decrease in fluorescein leakage. Change in intraocular pressure after intravitreal MTX was not significant. The aqueous humor levels of interleukin (IL) -6, IL-8, vascular endothelial growth factor, and monocyte chemotactic protein 1 were significantly higher in patients with Behcet disease compared with controls. The levels of IL-6 and IL-8 were significantly reduced at 4 weeks after intravitreal MTX, whereas those of vascular endothelial growth factor and monocyte chemotactic protein 1 were not reduced. CONCLUSION: Increased intraocular levels of IL-6, IL-8, vascular endothelial growth factor, and monocyte chemotactic protein 1 may be responsible for refractory retinal vasculitis in Behcet disease. Intravitreal MTX was associated with a significant reduction of IL-6 and IL-8 levels and was effective and well tolerated even in steroid responders with refractory retinal vasculitis due to Behcet disease.
机译:目的:本研究的目的是证明玻璃体内注射甲氨蝶呤(MTX)在治疗由于Behcet病引起的难治性视网膜血管炎中的作用,并评估玻璃体内注射甲氨蝶呤后房水细胞因子的变化。方法:对7例白塞病患者的7只眼进行了评估。患者患有单侧活动性视网膜血管炎,对常规治疗无效,并伴有眼内压升高或对皮质类固醇激素治疗不耐受的病史。每月一次玻璃体内注射400μgMTX,直到视力和眼内炎症稳定。作为对照组,从MTX注射前的患者和白内障手术期间的九只眼中获得患者的房水样品。分析了早期糖尿病性视网膜病变研究图的视力变化,荧光素血管造影术渗漏以及与玻璃体内注射相关的眼部并发症。使用多分析物生物芯片阵列系统通过蛋白质组学分析测量房水细胞因子水平。结果:在平均随访24.9±8.2周期间,视力显着改善,平均注射4.3±1.0后,基线视力从3.3±2.6线平均改善。 6例患者(85.7%)的视力增加了3条或更多行,而4例患者的荧光素泄漏减少了。玻璃体内MTX后眼压变化不显着。 Behcet病患者的房水白细胞介素(IL)-6,IL-8,血管内皮生长因子和单核细胞趋化蛋白1的水平明显高于对照组。玻璃体内MTX后4周,IL-6和IL-8的水平显着降低,而血管内皮生长因子和单核细胞趋化蛋白1的水平却没有降低。结论:白内障患者难治性视网膜血管炎可能是眼内IL-6,IL-8,血管内皮生长因子和单核细胞趋化蛋白1水平升高所致。玻璃体内MTX与IL-6和IL-8水平的显着降低有关,甚至在因贝塞特病引起的难治性视网膜血管炎的类固醇反应者中也有效且耐受性良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号